{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T06:45:00Z","timestamp":1794033900744,"version":"4.8.0"},"reference-count":151,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["ZIA-AA000242"],"award-info":[{"award-number":["ZIA-AA000242"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.pharmthera.2025.108957","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T05:11:48Z","timestamp":1763183508000},"page":"108957","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Treatment approaches for alcohol use disorder with metabolic dysfunction"],"prefix":"10.1016","volume":"277","author":[{"given":"Alexandra C.","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeesun","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pal","family":"Pacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk.W.","family":"Lohoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pharmthera.2025.108957_bb0005","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/08897077.2018.1475318","article-title":"All-cause and cause-specific mortality rates of patients treated for alcohol use disorders: A meta-analysis","volume":"39","author":"Abdul-Rahman","year":"2018","journal-title":"Substance Abuse"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0010","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2022.08.030","article-title":"Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease","volume":"78","author":"\u00c5berg","year":"2023","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108957_bb0015","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/acer.14271","article-title":"Interaction between alcohol use and metabolic risk factors for liver disease: A critical review of epidemiological studies","volume":"44","author":"\u00c5berg","year":"2020","journal-title":"Alcoholism: Clinical and Experimental Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108957_bb0020","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/hep.29631","article-title":"Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population","volume":"67","author":"\u00c5berg","year":"2018","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108957_bb0025","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1111\/jgh.16726","article-title":"Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake","volume":"39","author":"Aboona","year":"2024","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"9603","key":"10.1016\/j.pharmthera.2025.108957_bb0030","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: Randomised, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108957_bb0035","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ajcn\/88.4.1097","article-title":"Effect of moderate alcohol consumption on liver enzymes increases with increasing body mass index","volume":"88","author":"Alatalo","year":"2008","journal-title":"The American Journal of Clinical Nutrition"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108957_bb0040","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000133","article-title":"Prevalence of alcohol-associated liver disease: A systematic review and meta-analysis","volume":"7","author":"Amonker","year":"2023","journal-title":"Hepatology Communications"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104642","article-title":"Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats","volume":"93","author":"Aran\u00e4s","year":"2023","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108957_bb0050","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41395-018-0282-6","article-title":"Opportunities to prevent alcoholic liver cirrhosis in high-risk populations: A systematic review with Meta-analysis","volume":"114","author":"Askgaard","year":"2019","journal-title":"Official Journal of the American College of Gastroenterology | ACG"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0055","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108957_bb0060","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/hep.31496","article-title":"A randomized clinical trial of fecal microbiota transplant for alcohol use disorder","volume":"73","author":"Bajaj","year":"2021","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108957_bb0065","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/apt.14243","article-title":"Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study","volume":"46","author":"Bang","year":"2017","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108957_bb0070","doi-asserted-by":"crossref","first-page":"112","DOI":"10.7326\/0003-4819-132-2-200001180-00004","article-title":"Prevalence of and risk factors for hepatic steatosis in northern Italy","volume":"132","author":"Bellentani","year":"2000","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108957_bb0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/alcalc\/agq088","article-title":"Severe hypertriglyceridemia influenced by alcohol (SHIBA)","volume":"46","author":"Bessembinders","year":"2011","journal-title":"Alcohol and Alcoholism"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108957_bb0080","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/adb.12436","article-title":"The gut in the brain: The effects of bariatric surgery on alcohol consumption","volume":"22","author":"Blackburn","year":"2017","journal-title":"Addiction Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108957_bb0085","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jhep.2017.11.006","article-title":"The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease","volume":"68","author":"Boyle","year":"2018","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108957_bb0090","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/ije\/dyaa147","article-title":"Bariatric surgery and risk of alcohol use disorder: A register-based cohort study","volume":"49","author":"Bramming","year":"2020","journal-title":"International Journal of Epidemiology"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0095","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d636","article-title":"Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: Systematic review and meta-analysis of interventional studies","volume":"342","author":"Brien","year":"2011","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108957_bb0100","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/j.dsx.2019.06.021","article-title":"Proof of concept: Effect of GLP-1 agonist on food hedonic responses and taste sensitivity in poor controlled type 2 diabetic patients","volume":"13","author":"Brindisi","year":"2019","journal-title":"Diabetes and Metabolic Syndrome: Clinical Research and Reviews"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108957_bb0105","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"issue":"34","key":"10.1016\/j.pharmthera.2025.108957_bb0110","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: A meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104442","article-title":"The microbiome-gut-brain axis regulates social cognition & craving in young binge drinkers","volume":"89","author":"Carbia","year":"2023","journal-title":"eBioMedicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108957_bb0120","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.0305","article-title":"Combined association of body mass index and alcohol consumption with biomarkers for liver injury and incidence of liver disease: A Mendelian randomization study","volume":"2","author":"Carter","year":"2019","journal-title":"JAMA Network Open"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108957_bb0125","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S2215-0366(19)30222-6","article-title":"Psychiatric comorbidities in alcohol use disorder","volume":"6","author":"Castillo-Carniglia","year":"2019","journal-title":"The Lancet Psychiatry"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109096","article-title":"Statins and the risks of decompensated liver cirrhosis and hepatocellular carcinoma determined in patients with alcohol use disorder","volume":"228","author":"Chiu","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108957_bb0135","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108957_bb0140","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/liv.15939","article-title":"Impact of MASLD and MetALD on clinical outcomes: A meta-analysis of preliminary evidence","volume":"44","author":"Ciardullo","year":"2024","journal-title":"Liver International"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0145","article-title":"Diabetes complications in people with alcohol use disorder and type 2 diabetes","author":"Cook","year":"2024","journal-title":"BJGP open"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108957_bb0150","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: The state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0155","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0160","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/alcalc\/agn094","article-title":"Transitions in and out of alcohol use disorders: Their associations with conditional changes in quality of life over a 3-year follow-up interval","volume":"44","author":"Dawson","year":"2009","journal-title":"Alcohol and Alcoholism"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108957_bb0165","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41575-023-00822-y","article-title":"The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease","volume":"20","author":"D\u00edaz","year":"2023","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108957_bb0170","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes","volume":"7","author":"Do","year":"2024","journal-title":"JAMA Network Open"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108957_bb0175","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0306-4603(01)00204-0","article-title":"Adverse childhood experiences and personal alcohol abuse as an adult","volume":"27","author":"Dube","year":"2002","journal-title":"Addictive Behaviors"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108957_bb0180","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1097\/ADM.0000000000001084","article-title":"Simultaneous management of alcohol use disorder and liver disease: A systematic review and meta-analysis","volume":"17","author":"Elfeki","year":"2023","journal-title":"Journal of Addiction Medicine"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2025.108957_bb0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.drugalcdep.2011.12.007","article-title":"Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: A meta-analysis and meta-regression analysis [review]","volume":"122","author":"van Emmerik-van Oortmerssen","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108957_bb0190","doi-asserted-by":"crossref","DOI":"10.1172\/JCI188314","article-title":"Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake","volume":"135","author":"Farokhnia","year":"2025","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.109809","article-title":"A human laboratory study on the link between alcohol administration and circulating fibroblast growth factor 21 (FGF21) in individuals with alcohol use disorder","volume":"245","author":"Farokhnia","year":"2023","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0200","series-title":"Structured Clinical Interview for DSM-5\u2014Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV)","author":"First","year":"2015"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpath.2025.03.010","article-title":"An update on IL-22 therapies in alcohol-associated liver disease and beyond","author":"Fu","year":"2025","journal-title":"The American Journal of Pathology"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108957_bb0210","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1111\/dom.15216","article-title":"The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide","volume":"25","author":"Gasbjerg","year":"2023","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108957_bb0215","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","article-title":"Epidemiology of DSM-5 alcohol use disorder: Results from the National Epidemiologic Survey on alcohol and related conditions III","volume":"72","author":"Grant","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108957_bb0220","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1001\/archgenpsychiatry.2010.155","article-title":"The emerging link between alcoholism risk and obesity in the United States","volume":"67","author":"Grucza","year":"2010","journal-title":"Archives of General Psychiatry"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108957_bb0225","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/02698811231200880","article-title":"Treating posttraumatic stress disorder and alcohol use disorder comorbidity: Current pharmacological therapies and the future of MDMA-integrated psychotherapy","volume":"37","author":"Gully","year":"2023","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0230","author":"Hales"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108957_bb0235","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/0003319714549557","article-title":"Relationship between alcohol consumption and serum lipid profiles among middle-aged population in China: A multiple-center cardiovascular epidemiological study","volume":"66","author":"Hao","year":"2015","journal-title":"Angiology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108957_bb0240","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000996","article-title":"Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder","volume":"80","author":"Haque","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0245","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c1240","article-title":"Effect of body mass index and alcohol consumption on liver disease: Analysis of data from two prospective cohort studies","volume":"340","author":"Hart","year":"2010","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108957_bb0250","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/archpsyc.64.7.830","article-title":"Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: Results from the National Epidemiologic Survey on alcohol and related conditions","volume":"64","author":"Hasin","year":"2007","journal-title":"Archives of General Psychiatry"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108957_bb0255","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41386-020-00950-y","article-title":"Addiction as a brain disease revised: Why it still matters, and the need for consilience","volume":"46","author":"Heilig","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108957_bb0260","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly Semaglutide in adults with alcohol use disorder: A randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0265","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1038\/s41598-022-06010-3","article-title":"Prevalence and associations of metabolic syndrome in patients with alcohol use disorder","volume":"12","author":"Hern\u00e1ndez-Rubio","year":"2022","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108957_bb0270","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/hep.31031","article-title":"Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets [article]","volume":"72","author":"Hwang","year":"2020","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108957_bb0275","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41440-020-0417-1","article-title":"Alcohol consumption and risks of hypertension and cardiovascular disease in Japanese men and women","volume":"43","author":"Ikehara","year":"2020","journal-title":"Hypertension Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108957_bb0280","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000561","article-title":"Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists","volume":"8","author":"Jensen","year":"2024","journal-title":"Hepatol Commun"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108957_bb0285","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1194\/jlr.R119000547","article-title":"Alcohol effects on hepatic lipid metabolism","volume":"61","author":"Jeon","year":"2020","journal-title":"Journal of Lipid Research"},{"issue":"19","key":"10.1016\/j.pharmthera.2025.108957_bb0290","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108957_bb0295","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0893-133X(00)00195-0","article-title":"Drug addiction, dysregulation of reward, and Allostasis","volume":"24","author":"Koob","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108957_bb0300","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamainternmed.2019.2248","article-title":"Association of Weight Loss Interventions with Changes in biomarkers of nonalcoholic fatty liver disease: A systematic review and Meta-analysis","volume":"179","author":"Koutoukidis","year":"2019","journal-title":"JAMA Internal Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108957_bb0305","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/alcalc\/agaa068","article-title":"Mechanisms of alcohol addiction: Bridging human and animal studies","volume":"55","author":"Kramer","year":"2020","journal-title":"Alcohol and Alcoholism"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108957_bb0310","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/hep.32244","article-title":"Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease","volume":"75","author":"Kramer","year":"2022","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108957_bb0315","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and pharmacotherapy of alcohol use disorder: A review","volume":"320","author":"Kranzler","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0320","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/HEP.0000000000000925","article-title":"MASLD\/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up","volume":"81","author":"Kwak","year":"2025","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0325","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.05.031","article-title":"Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990\u20132014: A systematic review and meta-analysis","volume":"154","author":"Lai","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108957_bb0335","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108957_bb0340","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/jdi.13756","article-title":"Non-alcoholic fatty liver disease and type2 diabetes: An update","volume":"13","author":"Lee","year":"2022","journal-title":"Journal of Diabetes Investigation"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108957_bb0345","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1038\/s41591-023-02634-8","article-title":"GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders","volume":"29","author":"Leggio","year":"2023","journal-title":"Nature Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108957_bb0350","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/hep.32531","article-title":"Alcohol use disorder in community management of chronic liver diseases","volume":"77","author":"Leggio","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108957_bb0355","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/add.15646","article-title":"Association of alcohol use disorder on alcohol-related cancers, diabetes, ischemic heart disease and death: A population-based, matched cohort study","volume":"117","author":"Leong","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0360","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1016613","article-title":"Bariatric surgery and health outcomes: An umbrella analysis","volume":"13","author":"Liao","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108957_bb0365","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/s42255-023-00931-7","article-title":"Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice","volume":"5","author":"Liskiewicz","year":"2023","journal-title":"Nature Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0370","article-title":"Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury","volume":"6","author":"Liu","year":"2016","journal-title":"Scientific Reports"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108957_bb0375","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2217\/pgs-2020-0079","article-title":"Pharmacotherapies and personalized medicine for alcohol use disorder: A review","volume":"21","author":"Lohoff","year":"2020","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.767506","article-title":"Targeting unmet clinical needs in the treatment of alcohol use disorder [review]","volume":"13","author":"Lohoff","year":"2022","journal-title":"Frontiers in Psychiatry"},{"issue":"11\u221212","key":"10.1016\/j.pharmthera.2025.108957_bb0385","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/j.1365-2036.2009.04141.x","article-title":"Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: The rancho Bernardo study","volume":"30","author":"Loomba","year":"2009","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108957_bb0390","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrgastro.2015.35","article-title":"Alcoholic liver disease: Mechanisms of injury and targeted treatment","volume":"12","author":"Louvet","year":"2015","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0395","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1186\/s12889-022-13146-4","article-title":"Alcohol use disorder and its association with quality of life and mortality in Chinese male adults: A population-based cohort study","volume":"22","author":"Lu","year":"2022","journal-title":"BMC Public Health"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2025.108957_bb0400","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000447279","article-title":"Alcohol and obesity: A dangerous Association for Fatty Liver Disease","volume":"34","author":"Mahli","year":"2016","journal-title":"Digestive Diseases"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108957_bb0405","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2021.09.030","article-title":"Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus","volume":"76","author":"Mallet","year":"2022","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108957_bb0410","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1097\/HEP.0000000000000935","article-title":"MetALD: Does it require a different therapeutic option?","volume":"80","author":"Marek","year":"2024","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108957_bb0415","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","article-title":"Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease","volume":"81","author":"Marti-Aguado","year":"2024","journal-title":"Journal of Hepatology"},{"issue":"13","key":"10.1016\/j.pharmthera.2025.108957_bb0420","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical IllnessImplications for treatment, insurance, and outcomes evaluation","volume":"284","author":"McLellan","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0425","author":"National Institute on Alcohol Abuse and Alcoholism"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0430","author":"National Institute on Alcohol Abuse and Alcoholism"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0435","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4093\/dmj.2024.0042","article-title":"Metabolic dysfunction-associated Steatotic liver disease and all-cause and cause-specific mortality","volume":"49","author":"Oh","year":"2025","journal-title":"Diabetes and Metabolism Journal"},{"issue":"10060","key":"10.1016\/j.pharmthera.2025.108957_bb0440","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1016\/S0140-6736(16)31134-5","article-title":"A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: The lancet commission on hypertension","volume":"388","author":"Olsen","year":"2016","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108957_bb0445","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cgh.2019.04.048","article-title":"Alcohol rehabilitation within 30 days of hospital discharge is associated with reduced readmission, relapse, and death in patients with alcoholic hepatitis","volume":"18","author":"Peeraphatdit","year":"2020","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0450","doi-asserted-by":"crossref","first-page":"20998","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity","volume":"13","author":"Quddos","year":"2023","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108957_bb0455","first-page":"135","article-title":"The risks associated with alcohol use and alcoholism","volume":"34","author":"Rehm","year":"2011","journal-title":"Alcohol Research & Health"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0460","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12875-015-0308-8","article-title":"Alcohol dependence and treatment utilization in Europe \u2013 A representative cross-sectional study in primary care","volume":"16","author":"Rehm","year":"2015","journal-title":"BMC Family Practice"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108957_bb0465","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/acer.12331","article-title":"Burden of disease associated with alcohol use disorders in the United States","volume":"38","author":"Rehm","year":"2014","journal-title":"Alcoholism: Clinical and Experimental Research"},{"issue":"9682","key":"10.1016\/j.pharmthera.2025.108957_bb0470","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(09)60746-7","article-title":"Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders","volume":"373","author":"Rehm","year":"2009","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108957_bb0475","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1465-3362.2009.00153.x","article-title":"Alcohol as a risk factor for liver cirrhosis: A systematic review and meta-analysis","volume":"29","author":"Rehm","year":"2010","journal-title":"Drug and Alcohol Review"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0480","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-025-03199-3","article-title":"Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: A multi-ancestry drug-target Mendelian randomization study","author":"Reitz","year":"2025","journal-title":"Molecular Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0485","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1176\/appi.ajp.2017.1750101","article-title":"The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder","volume":"175","author":"Reus","year":"2018","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108957_bb0490","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"16","key":"10.1016\/j.pharmthera.2025.108957_bb0495","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of Alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0500","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and Reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Network Open"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108957_bb0505","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/S2468-2667(17)30003-8","article-title":"The effect of a reduction in alcohol consumption on blood pressure: A systematic review and meta-analysis","volume":"2","author":"Roerecke","year":"2017","journal-title":"The Lancet Public Health"},{"issue":"13","key":"10.1016\/j.pharmthera.2025.108957_bb0510","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008202","article-title":"Sex-specific associations between alcohol consumption and incidence of hypertension: A systematic review and Meta-analysis of cohort studies","volume":"7","author":"Roerecke","year":"2018","journal-title":"Journal of the American Heart Association"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108957_bb0515","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/hep.31042","article-title":"Impact of alcohol use disorder treatment on clinical outcomes among patients with cirrhosis","volume":"71","author":"Rogal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0520","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.pbb.2017.01.001","article-title":"Food and drug addictions: Similarities and differences","volume":"153","author":"Rogers","year":"2017","journal-title":"Pharmacology Biochemistry and Behavior"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0525","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cmet.2019.12.002","article-title":"Leveraging human genetics to identify potential new treatments for fatty liver disease","volume":"31","author":"Romeo","year":"2020","journal-title":"Cell Metabolism"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108957_bb0530","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jacc.2022.05.041","article-title":"Mendelian randomization study of PCSK9 and HMG-CoA reductase inhibition and cognitive function","volume":"80","author":"Rosoff","year":"2022","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108957_bb0535","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.5844","article-title":"Association of high-intensity binge drinking with lipid and liver function enzyme levels","volume":"2","author":"Rosoff","year":"2019","journal-title":"JAMA Network Open"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108957_bb0540","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003410","article-title":"Evaluating the relationship between alcohol consumption, tobacco use, and cardiovascular disease: A multivariable Mendelian randomization study","volume":"17","author":"Rosoff","year":"2020","journal-title":"PLoS Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0545","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41562-024-02040-1","article-title":"A multi-omics Mendelian randomization study identifies new therapeutic targets for alcohol use disorder and problem drinking","volume":"9","author":"Rosoff","year":"2025","journal-title":"Nature Human Behaviour"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108957_bb0550","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S1542-3565(05)00743-3","article-title":"Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population","volume":"3","author":"Ruhl","year":"2005","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"18","key":"10.1016\/j.pharmthera.2025.108957_bb0555","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0560","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.eurpsy.2013.08.006","article-title":"Co-morbid anxiety disorders predict early relapse after inpatient alcohol treatment","volume":"30","author":"Schellekens","year":"2015","journal-title":"European Psychiatry"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108957_bb0565","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1111\/acer.15172","article-title":"A randomized controlled trial of recovery management checkups for primary care patients: Twelve-month results","volume":"47","author":"Scott","year":"2023","journal-title":"Alcohol Clin Exp Res (Hoboken)"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150742","article-title":"Liver-specific thyroid hormone receptor-\u03b2 agonism alleviates alcoholic steatohepatitis (ASH) in mice","volume":"734","author":"Shahi","year":"2024","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0575","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/DMSO.S141235","article-title":"Reasons for discontinuation of GLP1 receptor agonists: Data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes","volume":"10","author":"Sikirica","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108957_bb0580","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa1912035","article-title":"Association of Aspirin with hepatocellular carcinoma and liver-related mortality","volume":"382","author":"Simon","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0585","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jpsychires.2016.06.022","article-title":"The association between post-traumatic stress disorder and lifetime DSM-5 psychiatric disorders among veterans: Data from the National Epidemiologic Survey on alcohol and related conditions-III (NESARC-III)","volume":"82","author":"Smith","year":"2016","journal-title":"Journal of Psychiatric Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108957_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2024.101127","article-title":"Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score","volume":"6","author":"Sripongpun","year":"2024","journal-title":"JHEP Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0595","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/biom7010016","article-title":"Alcohol, adipose tissue and lipid dysregulation","volume":"7","author":"Steiner","year":"2017","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108957_bb0600","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.amjmed.2005.01.007","article-title":"The prevalence and impact of alcohol problems in major depression: A systematic review [review]","volume":"118","author":"Sullivan","year":"2005","journal-title":"American Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108957_bb0610","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jsat.2011.03.005","article-title":"Depressive symptoms as a predictor of alcohol relapse after residential treatment programs for alcohol use disorder","volume":"41","author":"Suter","year":"2011","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108957_bb0615","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/alcalc\/agw046","article-title":"Overview of the genetics of alcohol use disorder","volume":"51","author":"Tawa","year":"2016","journal-title":"Alcohol and Alcoholism"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108957_bb0620","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00213-018-5089-z","article-title":"Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys","volume":"236","author":"Thomsen","year":"2019","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0625","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1186\/s12889-024-18318-y","article-title":"Risk of diabetes and hypertension in a population with alcohol use disorders","volume":"24","author":"Tseng","year":"2024","journal-title":"BMC Public Health"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0630","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.908948","article-title":"Genetic variability of incretin receptors and alcohol dependence: A pilot study","volume":"15","author":"Tsermpini","year":"2022","journal-title":"Frontiers in Molecular Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108957_bb0635","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00281-009-0152-9","article-title":"The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: Two triggers for one disease?","volume":"31","author":"Valenti","year":"2009","journal-title":"Seminars in Immunopathology"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108957_bb0640","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/alcalc\/agw040","article-title":"The prevalence of metabolic syndrome in alcohol use disorders: A systematic review and meta-analysis","volume":"51","author":"Vancampfort","year":"2016","journal-title":"Alcohol and Alcoholism"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108957_bb0645","doi-asserted-by":"crossref","first-page":"e2213014","DOI":"10.1001\/jamanetworkopen.2022.13014","article-title":"Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder","volume":"5","author":"Vannier","year":"2022","journal-title":"JAMA Network Open"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108957_bb0650","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1017\/S0033291714002165","article-title":"The heritability of alcohol use disorders: A meta-analysis of twin and adoption studies","volume":"45","author":"Verhulst","year":"2015","journal-title":"Psychological Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108957_bb0655","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMra1511480","article-title":"Neurobiologic advances from the brain disease model of addiction","volume":"374","author":"Volkow","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108957_bb0660","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1523\/JNEUROSCI.4877-14.2015","article-title":"Alcohol decreases baseline brain glucose metabolism more in heavy drinkers than controls but has no effect on stimulation-induced metabolic increases","volume":"35","author":"Volkow","year":"2015","journal-title":"The Journal of Neuroscience"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108957_bb0665","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.biopsych.2012.12.020","article-title":"The addictive dimensionality of obesity","volume":"73","author":"Volkow","year":"2013","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0670","article-title":"GLP-1R agonist medications for addiction treatment","author":"Volkow","year":"2024","journal-title":"Addiction"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0675","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.bbi.2024.04.022","article-title":"PCSK9 inhibition attenuates alcohol-associated neuronal oxidative stress and cellular injury","volume":"119","author":"Wagner","year":"2024","journal-title":"Brain, Behavior, and Immunity"},{"key":"10.1016\/j.pharmthera.2025.108957_bib753","author":"Wagner","year":"2025","journal-title":"Alcohol use disorder with metabolic dysfunction is associated with adverse health impacts in a United States clinical setting"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108957_bb0680","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s40211-020-00380-8","article-title":"Association of fibroblast growth factor 21 with alcohol consumption and alcohol liver cirrhosis","volume":"35","author":"Wagner-Skacel","year":"2021","journal-title":"Neuropsychiatrie"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119161","article-title":"Liver and atherosclerotic risk of alcohol consumption in patients with metabolic dysfunction-associated Steatotic liver disease","volume":"403","author":"Wang","year":"2025","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0690","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population","volume":"15","author":"Wang","year":"2024","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0695","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.2147\/PPA.S277676","article-title":"Real-world adherence and discontinuation of glucagon-like Peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States","volume":"14","author":"Weiss","year":"2020","journal-title":"Patient Preference and Adherence"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108957_bb0700","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/acer.14071","article-title":"Do associations between alcohol use and alcohol use disorder vary by weight status? Results from the National Epidemiologic Survey on alcohol and related conditions-III","volume":"43","author":"White","year":"2019","journal-title":"Alcoholism: Clinical and Experimental Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108957_bb0705","doi-asserted-by":"crossref","first-page":"106","DOI":"10.14309\/ajg.0000000000000833","article-title":"Obesity, diabetes, coffee, tea, and Cannabis use Alter risk for alcohol-related cirrhosis in 2 large cohorts of high-risk drinkers","volume":"116","author":"Whitfield","year":"2021","journal-title":"Official Journal of the American College of Gastroenterology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108957_bb0710","doi-asserted-by":"crossref","first-page":"471","DOI":"10.15288\/jsad.2020.81.471","article-title":"Increased morbidity and mortality in hypertensive patients with substance use disorders: Electronic health record findings","volume":"81","author":"Winhusen","year":"2020","journal-title":"Journal of Studies on Alcohol and Drugs"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0715","series-title":"Global Status Report on Alcohol and Health and Treatment of Substance Use Disorders","author":"World Health Organization","year":"2024"},{"key":"10.1016\/j.pharmthera.2025.108957_bb0720","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev-pathmechdis-031521-030435","article-title":"Recent advances in understanding of pathogenesis of alcohol-associated liver disease","volume":"18","author":"Wu","year":"2023","journal-title":"Annual Review of Pathology: Mechanisms of Disease"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108957_bb0725","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jacc.2017.06.054","article-title":"Relationship of alcohol consumption to all-cause, cardiovascular, and cancer-related mortality in U.S. adults","volume":"70","author":"Xi","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108957_bb0730","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/j.gastro.2016.03.005","article-title":"Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108957_bb0735","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108957_bb0740","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1542-3565(04)00014-X","article-title":"Nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"2","author":"Younossi","year":"2004","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108957_bb0745","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.cgh.2018.11.033","article-title":"Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease","volume":"17","author":"Younossi","year":"2019","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108957_bb0750","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/hep.32294","article-title":"Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease","volume":"76","author":"Zhang","year":"2022","journal-title":"Hepatology"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582500169X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582500169X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T01:53:08Z","timestamp":1766109188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016372582500169X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":151,"alternative-id":["S016372582500169X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108957","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment approaches for alcohol use disorder with metabolic dysfunction","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108957","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108957"}}